LNG 1.5 mg for Birth Control

Phase 4

Waitlist Available

Research Sponsored by Health Decisions

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

This trial will study if the morning-after pill is effective for women who weigh more than 80 kg and have unprotected sex.

Eligible Conditions

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

3Treatment groups

Active Control

Group I: LNG 1.5 mgActive Control1 Intervention

Group II: UPA 30mgActive Control1 Intervention

Group III: LNG 3.0Active Control1 Intervention

Do I qualify?Apply below to find out

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH

2,014 Previous Clinical Trials

2,695,634 Total Patients Enrolled

Health DecisionsLead Sponsor

30 Previous Clinical Trials

12,697 Total Patients Enrolled

Diana Blithe, PhDStudy DirectorNICHD Director

2 Previous Clinical Trials

2,092 Total Patients Enrolled

~167 spots leftby Sep 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.